While tech IPOs are at a standstill with current market conditions, biotech IPOs have kept a torrid pace since the beginning of 2013. 167 biotechs have gone public during that timeframe, according to the PitchBook Platform, nearly equal to the total from 2005 to 2012. Among the beneficiaries of the recent boom in biotech IPOs have been the 394 VC investors that have exited at least one of the companies to go public. 13 of the VC firms each invested in at least 10 of the biotechs to IPO since 2013.
Top VC investors in biotechs that have completed an IPO since 2013, along with their deal counts: